Evidence map›Paper›PMID 27404184›Full record

Trial reportJAMA2016

Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial.

Lisa R Metsch, Daniel J Feaster, Lauren Gooden, Tim Matheson, Maxine Stitzer, Moupali Das, Mamta K Jain, Allan E Rodriguez, Wendy S Armstrong, Gregory M Lucas and 22 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in JAMA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01612169 (NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users), which is not on this map. Cited by 139 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01612169 nacompletednot on this map

NIDA CTN Protocol 0049. Project HOPE -- Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users

TypeinterventionalSponsorColumbia UniversityRan2012 to 2015Enrolled801ConditionsHIV, AIDS, Substance Abuse, InpatientArmsPatient Navigation (PN) Group, Patient Navigator Plus Contingency Management (PN+CM) Group
3 · Its place in the literature

Who cites it

139 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Guideline
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

79 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Lisa R MetschDepartment of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, New York.
Daniel J FeasterDepartment of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, Florida.
Lauren GoodenDepartment of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, New York.
Tim MathesonSan Francisco Department of Public Health, San Francisco, California.
Maxine StitzerDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Moupali DasSan Francisco Department of Public Health, San Francisco, California5San Francisco General Hospital, San Francisco, California6University of California, San Francisco.
Mamta K JainDivision of Infectious Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas8Parkland Health and Hospital System, Dallas, Texas.
Allan E RodriguezDivision of Infectious Diseases, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida.
Wendy S ArmstrongDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
Gregory M LucasJohns Hopkins University School of Medicine, Baltimore, Maryland.
Ank E NijhawanDivision of Infectious Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
Mari-Lynn DrainoniDepartment of Health Law, Policy and Management, Boston University School of Public Health, Boston, Massachusetts13Section of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.
Patricia HerreraRuth M. Rothstein CORE Center, John H. Stroger, Jr, Hospital of Cook County, Chicago, Illinois.
Pamela Vergara-RodriguezRuth M. Rothstein CORE Center, John H. Stroger, Jr, Hospital of Cook County, Chicago, Illinois.
Jeffrey M JacobsonDivision of Infectious Diseases, Drexel University College of Medicine, Philadelphia, Pennsylvania16Department of Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania17Department of Neuroscience, Lewis Katz School of Medi.
Michael J MugaveroDivision of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham.
Meg SullivanSection of Infectious Diseases, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts.
Eric S DaarLos Angeles Biomedical Research Institute at Harbor-University of California Los Angeles Medical Center, Torrance.
Deborah K McMahonUniversity of Pittsburgh, Pittsburgh, Pennsylvania.
David C FerrisMount Sinai St Luke's and Mount Sinai West Hospitals, New York, New York23Icahn School of Medicine at Mount Sinai, New York, New York.
Robert LindbladThe Emmes Corporation, Rockville, Maryland.
Paul VanVeldhuisenThe Emmes Corporation, Rockville, Maryland.
Neal OdenThe Emmes Corporation, Rockville, Maryland.
Pedro C CastellónDepartment of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York, New York.
Susan TrossHIV Center for Clinical and Behavioral Studies, Division of Gender, Sexuality and Health, Department of Psychiatry, Columbia University Medical Center, New York, New York26Greater New York Node, National Drug Abuse Treatment Clinical Trials Network, Subst.
Louise F HaynesDivision of Addiction Sciences, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina.
Antoine DouaihyUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
James L SorensenWestern States Node, National Drug Abuse Treatment Clinical Trials Network, Department of Psychiatry, University of California, San Francisco.
David S MetzgerDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia31Treatment Research Institute, Philadelphia, Pennsylvania.
Raul N MandlerCenter for the Clinical Trials Network, National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
Grant N ColfaxSan Francisco Department of Public Health, San Francisco, California.
Carlos del RioDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia33Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia.

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Project-004UG1DA020024 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI Steven J Shoptaw, MADHUKAR H. TRIVEDI · 2015 to 2026
$71.6M
FLORIDA NODE OF THE DRUG ABUSE CLINICAL TRIALS NETWORKU10DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI METSCH, LISA R, SZAPOCZNIK, JOSE · 2000 to 2015
$56.9M
The National Drug Abuse Treatment Clinical Trials NetworkU10DA013045 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LING, WALTER NMN · 1999 to 2015
$52.6M
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkUG1DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel J Feaster, Viviana Elizabeth Horigian · 2015 to 2026
$50.6M
The Statistics, Data Science, and Data Management (SDM) CoreP30MH043520 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI Claude Ann Mellins · 2003 to 2026
$48.2M
CU PARTNERS: NY/LONG ISLAND REGIONAL NODEU10DA013035 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI NUNES, EDWARD V., ROTROSEN, JOHN P · 2001 to 2015
$47.6M
Clinical Trials Network, Ohio Valley Node U10DA013732U10DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI WINHUSEN, T JOHN · 2000 to 2015
$45.0M
The Ohio Valley Node of the Clinical Trials Network (CTN-0153)UG1DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI T John WINHUSEN · 2015 to 2026
$42.5M
Southern Consortium Node of the Clinical Trials NetworkU10DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2000 to 2015
$34.4M
NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1TR000454NIAID NIH HHS P30 AI050409NIAID NIH HHS P30AI050409NIAID NIH HHS P30 AI073961NIAID NIH HHS P30AI073961NIDA NIH HHS HHSN271200900034CNIDA NIH HHS HHSN271200900034C/N01DA92217NIDA NIH HHS HHSN271201000024CNIDA NIH HHS HHSN271201000024C/N01DA102221NIDA NIH HHS HHSN271201400028CNIDA NIH HHS HHSN271201400028C/N01DA142237NIDA NIH HHS K24 DA035684NIDA NIH HHS U10 DA013034NIDA NIH HHS U10DA013034NIDA NIH HHS U10 DA013035NIDA NIH HHS U10DA013035NIDA NIH HHS U10 DA013043NIDA NIH HHS U10DA013043NIDA NIH HHS U10 DA013045NIDA NIH HHS U10DA013045NIDA NIH HHS U10 DA013720NIDA NIH HHS U10DA013720NIDA NIH HHS U10 DA013727NIDA NIH HHS U10DA013727NIDA NIH HHS U10 DA013732NIDA NIH HHS U10DA013732NIDA NIH HHS U10 DA015815NIDA NIH HHS U10DA015815NIDA NIH HHS U10 DA015831NIDA NIH HHS U10DA015831NIDA NIH HHS U10 DA020024NIDA NIH HHS U10DA020024NIDA NIH HHS U10 DA020036NIDA NIH HHS U10DA020036NIDA NIH HHS UG1 DA013034NIDA NIH HHS UG1DA013034NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1DA013035NIDA NIH HHS UG1 DA013720NIDA NIH HHS UG1DA013720NIDA NIH HHS UG1 DA013727NIDA NIH HHS UG1DA013727NIDA NIH HHS UG1 DA013732NIDA NIH HHS UG1DA013732NIDA NIH HHS UG1 DA015815NIDA NIH HHS UG1DA015815NIDA NIH HHS UG1 DA015831NIDA NIH HHS UG1DA015831NIDA NIH HHS UG1 DA020024NIDA NIH HHS UG1DA020024NIMH NIH HHS P30 MH043520NIMH NIH HHS P30MH043520
6 · The paper itself

Abstract

importanceSubstance use is a major driver of the HIV epidemic and is associated with poor HIV care outcomes. Patient navigation (care coordination with case management) and the use of financial incentives for achieving predetermined outcomes are interventions increasingly promoted to engage patients in substance use disorders treatment and HIV care, but there is little evidence for their efficacy in improving HIV-1 viral suppression rates.

objectiveTo assess the effect of a structured patient navigation intervention with or without financial incentives to improve HIV-1 viral suppression rates among patients with elevated HIV-1 viral loads and substance use recruited as hospital inpatients. DESIGN, SETTING, AND

participantsFrom July 2012 through January 2014, 801 patients with HIV infection and substance use from 11 hospitals across the United States were randomly assigned to receive patient navigation alone (n = 266), patient navigation plus financial incentives (n = 271), or treatment as usual (n = 264). HIV-1 plasma viral load was measured at baseline and at 6 and 12 months.

interventionsPatient navigation included up to 11 sessions of care coordination with case management and motivational interviewing techniques over 6 months. Financial incentives (up to $1160) were provided for achieving targeted behaviors aimed at reducing substance use, increasing engagement in HIV care, and improving HIV outcomes. Treatment as usual was the standard practice at each hospital for linking hospitalized patients to outpatient HIV care and substance use disorders treatment. MAIN OUTCOMES AND MEASURES: The primary outcome was HIV viral suppression (≤200 copies/mL) relative to viral nonsuppression or death at the 12-month follow-up.

resultsOf 801 patients randomized, 261 (32.6%) were women (mean [SD] age, 44.6 years [10.0 years]). There were no differences in rates of HIV viral suppression versus nonsuppression or death among the 3 groups at 12 months. Eighty-five of 249 patients (34.1%) in the usual-treatment group experienced treatment success compared with 89 of 249 patients (35.7%) in the navigation-only group for a treatment difference of 1.6% (95% CI, -6.8% to 10.0%; P = .80) and compared with 98 of 254 patients (38.6%) in the navigation-plus-incentives group for a treatment difference of 4.5% (95% CI -4.0% to 12.8%; P = .68). The treatment difference between the navigation-only and the navigation-plus-incentives group was -2.8% (95% CI, -11.3% to 5.6%; P = .68). CONCLUSIONS AND RELEVANCE: Among hospitalized patients with HIV infection and substance use, patient navigation with or without financial incentives did not have a beneficial effect on HIV viral suppression relative to nonsuppression or death at 12 months vs treatment as usual. These findings do not support these interventions in this setting.

trial registrationclinicaltrials.gov Identifier: NCT01612169.

Indexed as

Case ManagementFinancing, PersonalHIV-1Patient NavigationAdultChildChild, PreschoolFemaleHIV InfectionsHumansInfantInpatientsMaleMiddle AgedMotivationMotivational Interviewing

Identifiers

PMID27404184
PMCPMC5339876

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.